Costs Attributable to Overweight and Obesity in Working Asthma Patients in the United States

Abstract

PurposeTo estimate annual health care and productivity loss costs attributable to overweight or obesity in working asthmatic patients.Materials and MethodsThis study was conducted using the 2003–2013 Medical Expenditure Panel Survey (MEPS) in the United States. Patients aged 18 to 64 years with asthma were identified via self-reported diagnosis, a Clinical Classification Code of 128, or a ICD-9-CM code of 493.xx. All-cause health care costs were estimated using a generalized linear model with a log function and a gamma distribution. Productivity loss costs were estimated in relation to hourly wages and missed work days, and a two-part model was used to adjust for patients with zero costs. To estimate the costs attributable to overweight or obesity in asthma patients, costs were estimated by the recycled prediction method.ResultsAmong 11670 working patients with a diagnosis of asthma, 4428 (35.2%) were obese and 3761 (33.0%) were overweight. The health care costs attributable to obesity and overweight in working asthma patients were estimated to be $878 [95% confidence interval (CI): $861–$895] and $257 (95% CI: $251–$262) per person per year, respectively, from 2003 to 2013. The productivity loss costs attributable to obesity and overweight among working asthma patients were $256 (95% CI: $253–$260) and $26 (95% CI: $26–$27) per person per year, respectively.ConclusionHealth care and productivity loss costs attributable to overweight and obesity in asthma patients are substantial. This study's results highlight the importance of effective public health and educational initiatives targeted at reducing overweight and obesity among patients with asthma, which may help lower the economic burden of asthma.

Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study

“…Another study estimated health care costs attributable to obesity and overweight in working patients with asthma to be $878 and $257 in 2015 USD, per person per year, from 2003-2013. 22 Our adjusted analysis of the asthma cohort found that patients with class III obesity were associated with 18.1% higher 1-year total complication-specific costs versus patients with normal weight (P < 0.0001).…”

Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model

“…Obesity accompanies various comorbid diseases including hypertension, diabetes, cardiovascular disease, renal insufficiency, and even cancer, and it causes tremendous economic burden 29,30 . Empagliflozin and dulaglutide could improve metabolic abnormality, lead to weight loss, and contribute to treating other obesity-related comorbid diseases 31,32 .…”

Regular follow-up visits reduce the risk for asthma exacerbation requiring admission in Korean adults with asthma

“…Second, we could not analyze the potential variables that affect the frequency of visits and prognosis due to the retrospective nature of this study. For instance, adherence to medication, the dose of the inhaler, socio-economic status, clinical characteristics, residential district, and weather may be influential factors [ 26 , 27 ]. In this retrospective study, which used claim data from a national medical insurance review system, the available variables were extremely restricted.…”